Provided by Tiger Fintech (Singapore) Pte. Ltd.

CytomX Therapeutics

2.25
-0.0600-2.60%
Post-market: 2.290.0400+1.78%19:54 EDT
Volume:2.54M
Turnover:5.86M
Market Cap:354.47M
PE:4.64
High:2.44
Open:2.32
Low:2.23
Close:2.31
Loading ...

Marcia Belvin, SVP and Chief Scientific Officer, Reports Disposal of Common Shares in CytomX Therapeutics Inc

Reuters
·
18 Jun

CEO Sean A. McCarthy Reports Disposal of Common Shares of CytomX Therapeutics Inc

Reuters
·
18 Jun

CytomX Therapeutics Approves Key Amendments at Annual Meeting

TIPRANKS
·
14 Jun

CytomX Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
14 Jun

CytomX Therapeutics Inc - Regains Compliance With Nasdaq Minimum Bid Price - SEC Filing

THOMSON REUTERS
·
29 May

CytomX Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
20 May

CytomX Therapeutics announces first patient dosed in Phase 1 study of CX-801

TIPRANKS
·
19 May

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of Cx-801 Plus Keytruda® (Pembrolizumab) in Patients With Metastatic Melanoma

THOMSON REUTERS
·
19 May

CytomX Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
16 May

HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5

MT Newswires Live
·
15 May

CytomX Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
15 May

CytomX Therapeutics Inc : Piper Sandler Raises Target Price to $5 From $2.5

THOMSON REUTERS
·
15 May

Sector Update: Health Care Stocks Climb Monday Afternoon

MT Newswires Live
·
13 May

CytomX Shares Jump After Q1 Beat, 'Positive' Interim Trial Data

MT Newswires Live
·
12 May

CytomX Therapeutics Inc : Wedbush Raises Target Price to $6 From $5

THOMSON REUTERS
·
12 May

Wedbush Adjusts CytomX Therapeutics Price Target to $6 From $5, Maintains Outperform Rating

MT Newswires Live
·
12 May

Top Premarket Gainers

MT Newswires Live
·
12 May

Press Release: CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Dow Jones
·
12 May

CytomX Therapeutics Reports Positive Interim Phase 1 Data

TIPRANKS
·
12 May

CytomX Therapeutics Q1 EPS $0.27 Beats $0.12 Estimate, Sales $50.92M Beat $30.84M Estimate

Benzinga
·
12 May